ESR(01821.HK)斥2億美元合資成立中國投資平台
ESR(01821.HK)公布,附屬ESR投資者與APG投資者及RECO投資者訂立共同投資平台協議,以設立一個共同投資平台「新中國發展平台」。相關平台為新的發展基金,將投資於由公司採購、開發和管理位於中國選定市場的倉儲或倉儲與工業混合用途物業。新中國發展平台由該等離岸合營企業構成,彼等將持有新中國發展平台投資的相關項目,ESR投資者將持有其各家的20%股權。
新中國發展平台初始資本承擔上限為合共10億美元,其中ESR投資者同意出資最多2億美元,APG投資者及RECO投資者同意出資最多4億美元。倘追資選擇權獲行使,ESR投資者應按相當於所有投資者全部資本承擔的20%的金額出資最高4億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.